Investor Relations :: Benitec Biopharma Inc. (BNTC)

Latest News

Nov 30, 2023

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

View Press Release

Nov 17, 2023

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

Nov 13, 2023

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

View All News

Corporate Presentation, July 2023

View Presentation

2023 Annual Meeting of Stockholders

View Event View All

Q1 2024

Quarter Ended Sep 30, 2023

Earnings Release

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2023

Company Overview

Benitec Biopharma Inc. is a development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.

View Management Team View Board of Directors

Investor Contact Information

Company

Benitec Biopharma Inc.
3940 Trust Way
Hayward, CA 94545

Investor Relations

Irina Koffler
Managing Director, LifeSci Advisors
T: 646-970-4681
ikoffler@lifesciadvisors.com

Transfer Agent

Computershare Investor Services
P.O. Box 505005
Louisville, KY 40233-5005
T: 781-575-3100